Isec Healthcare Ltd · SGX:40T
Isec Healthcare — FY2018 Earnings Presentation
20 slides from Isec Healthcare's earnings presentation, Feb 24, 2019
Slide 1: Corporate Presentation
Corporate Presentation 12 months ended 31 December 2018 Page 0
Slide 2: Sponsor disclaimer
This presentation has been prepared by the Company and its contents have been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”), for compliance with the Singapore Exchange Securities Trading Limited (the “SGX-ST”) Listing Manual Section B: Rules of Catalist
Slide 3: Table of Content
Table of Content Business Overview Competitive Strengths of the Group Business Strategy and Expansion Plans Corporate Developments and Use of Proceeds 12 months Financial Highlights for the Period Ended 31 December 2018 Page 2
Slide 4: Business Overview
Business Overview Page 3
Slide 5: Business Overview
Business Overview • Specialised Health Services – Medical eye care service provider • ISEC is a comprehensive medical eye care service provider, with ambulatory surgical centres in Malaysia (Kuala Lumpur, Penang, Malacca & Sibu) and provides specialist medical ophthalmology services to Lee Hung Ming
Slide 6: Competitive Strengths of the Group
Competitive Strengths of the Group Page 5
Slide 7: Competitive Strengths of the Group
Competitive Strengths of the Group 1 Highly qualified and experienced specialist doctors 6 Business model aligns the 2 interests of our High quality and specialist doctors with comprehensive range of our Group and eye care services Shareholders 5 Ability to replicate our 3 Well positioned to busines
Slide 8: Business Strategy and Expansion Plans
Business Strategy And Expansion Plans Page 7
Slide 9: Our Business Strategies
Our Business Strategies To reach out to more patients in locations where we currently operate, as well as new locations such as major Growing the ISEC cities or locations in Peninsular Malaysia, East Malaysia and Brand and Singapore Expanding into To expand via setting up of subsidiaries, joint
Slide 10: Expansion Plans: Business expansion in the Asia Pacific
Expansion Plans Business expansion in the Asia Pacific region (including Malaysia Malaysia & and Singapore) Singapore Target Countries Page 9
Slide 11: Corporate Developments and Use of Proceeds
Corporate Developments And Use of Proceeds Page 10
Slide 12: Corporate Developments
Corporate Developments JOINT VENTURE INTO ISEC MYANMAR COMPANY LIMITED ISEC Myanmar Company Limited (“ISEC Myanmar”) has obtained the approval of the Myanmar Investment Commission (“MIC”) in November 2018 for the joint venture with 3 independent third parties to operate and administer ophthalmology
Slide 13: Use of Proceeds
Use of Proceeds As at 26 February 2019 Amount allocated pursuant to reallocation of Use of proceeds Amount allocated unutilised listing Amount S$’000 expenses utilised Balance S$’000 S$’000 S$’000 Business expansion in Asia Pacific region (including Malaysia and 13,800 300 (13,041) (N1) 1,059 Singap
Slide 14: 12 Months Financial Highlights
12 Months Financial Highlights for the Period Ended 31 December 2018 Page 13
Slide 15: Revenue
Revenue 9.2% SGD’mil 10.7% 4.5% FY2018 vs FY2017 The increase in Group revenue was mainly attributable to increased patient visits from the Group’s specialised eye care services in Malaysia and Singapore. Page 14
Slide 16: Revenue – Malaysia
Revenue – Malaysia RM’mil SGD’mil 100.0 6.7% 100.0 92.8 90.0 87.0 90.0 80.0 80.0 70.0 70.0 60.0 60.0 50.0 50.0 10.7% 40.0 40.0 31.0 28.0 30.0 30.0 20.0 20.0 10.0 10.0 - - FY2017 FY2018 FY2017 FY2018 Revenue from Malaysia operations in Ringgit Malaysia (“RM”) increased from RM87.0 million in FY2017
Slide 17: EBITDA and Profit After Tax (PAT)
Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) and Profit After Tax (PAT) SGD’000 9.7% 14,000 12,788 12,000 11,657 10.0% 10,000 8,677 7,885 8,000 6,000 4,000 2,000 - EBITDA PAT FY2017 FY2018 EBITDA was S$12.8 million in FY2018 as compared to S$11.7 million in FY2017, an incr
Slide 18: Cash Position
Cash Position 27.1 Total cash and cash equivalents 24.8 1.1 Unutilised IPO proceeds 1.5 Cash balances 26.0 23.3 - 5.0 10.0 15.0 20.0 25.0 30.0 As at 31 Dec 2018 As at 31 Dec 2017 SGD’mil Total cash and cash equivalents as at 31 December 2018 was S$27.1 million. No debt. Cash balances (excluding
Slide 19: Statement of Financial Position
Statement of Financial Position S$’000 31 December 31 December 2018 2017 Key Assets Plant and equipment 3,735 3,894 Intangible assets 38,182^ 38,766^ Trade and other receivables 2,984 2,505 Cash and cash equivalents 27,105 24,824 Key Liabilities Trade and other payables 4,184 3,475 Equity Total equi
Slide 20: Thank You
Thank You Page 19